Viveve Medical (VIVE) 10-Q 9 May 19 2019 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2019	May 08, 2019
Document Information [Line Items]
Entity Registrant Name	VIVEVE MEDICAL, INC.
Entity Central Index Key	0000879682
Trading Symbol	vive
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		46,488,801
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 17,821,000	$ 29,523,000
Accounts receivable, net of allowance for doubtful accounts of $395 and $284 as of March 31, 2019 and December 31, 2018, respectively	4,778,000	5,704,000
Inventory	3,867,000	4,119,000
Prepaid expenses and other current assets	3,117,000	2,558,000
Total current assets	29,583,000	41,904,000
Property and equipment, net	2,832,000	2,916,000
Investment in limited liability company	1,718,000	1,843,000
Other assets	719,000	171,000
Total assets	34,852,000	46,834,000
Current liabilities:
Accounts payable	2,686,000	3,994,000
Accrued liabilities	4,802,000	6,766,000
Total current liabilities	7,488,000	10,760,000
Note payable, noncurrent portion	30,927,000	30,528,000
Other noncurrent liabilities	1,023,000	634,000
Total liabilities	39,438,000	41,922,000
Commitments and contingences (Note 8)
Stockholders’ equity (deficit):
Common stock, $0.0001 par value; 75,000,000 shares authorized as of March 31, 2019 and December 31, 2018; 46,435,802 and 46,363,945 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively	5,000	5,000
Additional paid-in capital	160,823,000	160,292,000
Accumulated deficit	(165,414,000)	(155,385,000)
Total stockholders’ equity (deficit)	(4,586,000)	4,912,000
Total liabilities and stockholders’ equity (deficit)	$ 34,852,000	$ 46,834,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Accounts receivable, allowance for doubtful accounts	$ 395	$ 284
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	46,435,802	46,363,945
Common stock, shares outstanding (in shares)	46,435,802	46,363,945

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenue	$ 3,012,000	$ 3,699,000
Cost of revenue	1,941,000	2,352,000
Gross profit	1,071,000	1,347,000
Operating expenses:
Research and development	2,480,000	3,756,000
Selling, general and administrative	6,626,000	8,931,000
Restructuring costs	742,000
Total operating expenses	9,848,000	12,687,000
Loss from operations	(8,777,000)	(11,340,000)
Interest expense, net	(1,116,000)	(1,070,000)
Other expense, net	(11,000)	(10,000)
Net loss from consolidated companies	(9,904,000)	(12,420,000)
Loss from minority interest in limited liability company	(125,000)	(249,000)
Comprehensive and net loss	$ (10,029,000)	$ (12,669,000)
Net loss per share:
Basic and diluted (in dollars per share)	$ (0.22)	$ (0.49)
Weighted average shares used in computing net loss per common share:
Basic and diluted (in shares)	46,371,891	25,846,724

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	February 2018 Offering [Member]Common Stock [Member]	February 2018 Offering [Member]Additional Paid-in Capital [Member]	February 2018 Offering [Member]	November 2017 ATM Facility [Member]Common Stock [Member]	November 2017 ATM Facility [Member]Additional Paid-in Capital [Member]	November 2017 ATM Facility [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balances (in shares) at Dec. 31, 2017							19,503,558
Balances at Dec. 31, 2017							$ 2	$ 102,979	$ (105,581)	$ (2,600)
Stock-based compensation expense								645		645
Issuance of common shares from employee stock purchase plan (in shares)							20,744
Issuance of common shares from employee stock purchase plan								65		65
Issuance of restricted shares (in shares)							22,137
Issuance of restricted shares								108		108
Net loss									(12,669)	(12,669)
Stock offering, net of issuance costs (in shares)	11,500,000			208,277		208,277
Stock offering, net of issuance costs	$ 1	$ 32,224	$ 32,225		$ 1,011	$ 1,011
Balances (in shares) at Mar. 31, 2018							31,254,716
Balances at Mar. 31, 2018							$ 3	137,032	(118,073)	18,962
Cumulative effect adjustment from adoption of new accounting standard – ASC 606									177	177
Balances (in shares) at Dec. 31, 2018							46,363,945
Balances at Dec. 31, 2018							$ 5	160,292	(155,385)	4,912
Stock-based compensation expense								470		470
Issuance of common shares from employee stock purchase plan (in shares)							43,759
Issuance of common shares from employee stock purchase plan								35		35
Issuance of restricted shares (in shares)							27,473
Issuance of restricted shares								25		25
Issuance of common shares in connection with restricted stock award to employee (in shares)							625
Issuance of common shares in connection with restricted stock award to employee								1		1
Net loss									(10,029)	(10,029)
Stock offering, net of issuance costs (in shares)						0
Balances (in shares) at Mar. 31, 2019							46,435,802
Balances at Mar. 31, 2019							$ 5	$ 160,823	$ (165,414)	$ (4,586)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities:
Net loss	$ (10,029,000)	$ (12,669,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Provision for doubtful accounts	111,000	42,000
Depreciation and amortization	311,000	150,000
Stock-based compensation	496,000	753,000
Non-cash interest expense	399,000	386,000
Amortization of operating lease right-of-use assets and accretion of operating lease liabilities	10,000
Loss from minority interest in limited liability company	125,000	249,000
Changes in assets and liabilities:
Accounts receivable	815,000	(828,000)
Inventory	206,000	(1,497,000)
Prepaid expenses and other current assets	(559,000)	(561,000)
Other noncurrent assets	17,000	(2,000)
Accounts payable	(1,310,000)	(934,000)
Accrued and other liabilities	(2,202,000)	(366,000)
Other noncurrent liabilities	52,000	86,000
Net cash used in operating activities	(11,558,000)	(15,191,000)
Cash flows from investing activities:
Purchase of property and equipment	(179,000)	(462,000)
Net cash used in investing activities	(179,000)	(462,000)
Cash flows from financing activities:
Proceeds from sale of common stock, net of issuance costs		33,236,000
Proceeds from issuance of common shares from employee stock purchase plan	35,000	65,000
Net cash provided by financing activities	35,000	33,301,000
Net increase (decrease) in cash and cash equivalents	(11,702,000)	17,648,000
Cash and cash equivalents - beginning of period	29,523,000	20,730,000
Cash and cash equivalents - end of period	17,821,000	38,378,000
Supplemental disclosure:
Cash paid for interest	675,000	653,000
Cash paid for income taxes
Supplemental disclosure of cash flow information as of end of period:
Issuance of note payable in settlement of accrued interest	318,000	305,000
Net transfer of equipment between inventory and property and equipment	46,000	59,000
Operating cash outflows from operating leases	73,000
Right-of-use assets obtained in exchange for operating lease liabilities (upon adoption of ASC 842)	$ 629,000

Note 1 - The Company and Basis

Note 1 - The Company and Basis of Presentation	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. The Company and Basis of Presentation Viveve Medical, Inc. (“Viveve Medical”, the “Company”, “we”, “our”, or “us”) designs, develops, manufactures and markets a platform medical technology, which we refer to as Cryogen-cooled Monopolar RadioFrequency Public Offerings In December 2018, “December 2018 14,728,504 $1.50 $22,093,000. $20,385,000. In February 2018, “February 2018 11,500,000 $3.00 $34,500,000. $32,214,000. The Company established an “at-the-market” equity offering program through the filing of a prospectus supplement to its shelf registration statement on Form S- 3, November 8, 2017, may $25,000,000 “November 2017 three March 31, 2019, zero November 2017 three March 31, 2018, 208,277 November 2017 $1,011,000. March 31, 2019, 336,498 November 2017 $1,318,000. Interim Unaudited Financial Information The accompanying unaudited condensed consolidated financial statements of Viveve Medical have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10 8 03 X. not The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Annual Report on Form 10 December 31, 2018, March 15, 2019. three March 31, 2019 not December 31, 2019 Liquidity and Management Plans The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standard Codification (“ASC”) Topic 205 40, one The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. However, since inception, the Company has sustained significant operating losses and such losses are expected to continue for the foreseeable future. As of March 31, 2019, $165,414,000, $17,821,000 $22,095,000. $11,558,000 three March 31, 2019. May 9, 2020. not one January 2019, November 2017 To fund further operations, the Company will need to raise additional capital. The Company may no not no

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Financial Statement Presentation The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may Changes in Accounting Policies Except for the changes for the adoption of the new revenue recognition accounting standard, the Company has consistently applied the accounting policies to all periods presented in these condensed consolidated financial statements. Adoption of New Accounting Standard - Leases The Company adopted FASB’s Accounting Standards Update (“ASU”) No. 2016 02, 842 January 1, 2019, $629,000 $629,000, January 1, 2019. not not The effect of the changes made to our consolidated January 1, 2019 Adjustments Due to December 31, Adoption of January 1, 2018 ASC 842 2019 Other assets $ 171 $ 629 (1) $ 800 Total assets $ 46,834 $ 629 (1) $ 47,463 Accrued liabilities $ 6,766 $ 230 (2) $ 6,996 Total current liabilities $ 10,760 $ 230 (2) $ 10,990 Other noncurrent liabilities $ 634 $ 399 (2) $ 1,033 Total liabilities $ 41,922 $ 629 (2) $ 42,551 Total liabilities and stockholders' equity $ 46,834 $ 629 (2) $ 47,463 ( 1 Represents capitalization of operating lease right-of-use assets and reclassification of deferred rent. ( 2 Represents recognition of operating lease liabilities. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three one may, Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no Most of the Company’s products to date require clearance or approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device that it refers to as the Viveve System, which is intended for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, for use in general surgical procedures for electrocoagulation and hemostasis, and stress urinary incontinence, depending on the relevant country-specific clearance or approval. The Viveve System consists of three four five third In North America, the Company sells its products primarily through a direct sales force to health care practitioners. Outside North America, the Company sells through an extensive network of distribution partners. During the three March 31, 2019, three 42% three March 31, 2018, two 54% no 10% three March 31, 2019 2018. As of March 31, 2019, four 62% December 31, 2018, three 54% Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not six may six not $395,000 March 31, 2019 $284,000 December 31, 2018. Revenue Recognition Revenue consists primarily of the sale of the Viveve System, single-use treatment tips and ancillary consumables. The Company applies the following five 1 2 3 4 5 Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance for differing indications, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. In North America, we market and sell primarily through a direct sales force. Outside of North America, we market and sell primarily through distribution partners. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Contract Assets and Liabilities The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No March 31, 2019 December 31, 2018. $679,000, not March 31, 2019 $686,000 December 31, 2018. The following table reflects the changes in our customer contract liabilities for the three March 31, 2019: March 31, December 31, Three Months 2019 2018 Change Customer contracts liabilities: Marketing programs $ 627 $ 639 $ (12 ) Other 52 47 5 Total $ 679 $ 686 $ (7 ) Separately, accounts receivable, net represents receivables from contracts with customers. Significant Financing Component The Company applies the practical expedient to not not one three March 31, 2019 2018, not Contract Costs The Company has elected the practical expedient to recognize the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that the Company otherwise would have recognized is one three March 31, 2019 2018, one Shipping and Handling Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. Revenue by Geographic Area Management has determined that the sales by geography is a key indicator for understanding the Company’s financials because of the different sales and business models that are required in the various regions of the world (including regulatory, selling channels, pricing, customers and marketing efforts). The following table presents the revenue from unaffiliated customers disaggregated by geographic area for the three March 31, 2019 2018 Three Months Ended March 31, 2019 2018 North America $ 1,792 $ 2,606 Asia Pacific 967 891 Europe and Middle East 246 202 Latin America 7 - Total $ 3,012 $ 3,699 The Company determines geographic location of its revenue based upon the destination of the shipments of its products. Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not 1 2 3 three not The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee’s business segment might indicate a loss in value. The carrying value of the investments is reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not No three March 31, 2019 2018. Product Warranty The Company’s products are generally subject to warranties between one three not Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee’s service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. The Company determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option’s expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded at their fair value on the measurement date and are subject to periodic adjustment as the underlying equity instruments vest. Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may three March 31, 2019 2018, Net Loss per Share The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. Three Months Ended March 31, 2019 2018 Stock options to purchase common stock 5,593,130 3,690,902 Warrants to purchase common stock 642,622 642,622 Restricted common stock awards 419,147 22,500 Other Recently Issued and Adopted Accounting Standards In June 2018, 2018 07, 718 718 718 December 15, 2018, January 1, 2019 not We have reviewed other recent accounting pronouncements and concluded they are either not no

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Fair Value Disclosures [Text Block]	3. Fair Value Measurements The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 3 Level 1 Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Therefore, determining fair value for Level 1 not not Level 2 Pricing is provided by third not Level 3 Inputs used to measure fair value are unobservable inputs that are supported by little or no 3 Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. There were no March 31, 2019 December 31, 2018. The carrying amounts of the Company’s financial assets and liabilities, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses as of March 31, 2019, December 31, 2018 There were no

Note 4 - Investment in Limited

Note 4 - Investment in Limited Liability Company	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Equity Method Investments and Joint Ventures Disclosure [Text Block]	4. Investment in Limited Liability Company On August 8, 2017, Under the terms of the Distributorship Agreement, ICM agreed to not third not March 31, 2019, 4,800 $27,000 three March 31, 2019. no March 31, 2019 December 31, 2018. In connection with the Distributorship Agreement, the Company also entered into a Membership Unit Subscription Agreement with ICM and the associated limited liability company operating agreement of ICM, pursuant to which the Company invested $2,500,000 not March 31, 2019, 9% three three March 31, 2019, $125,000 In February 2019, no

Note 5 - Accrued Liabilities

Note 5 - Accrued Liabilities	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	5. Accrued Liabilities Accrued liabilities consisted of the following as of March 31, 2019 December 31, 2018 ( March 31, December 31, 2019 2018 Accrued sales commission $ 817 $ 1,743 Customer contracts liabilities 679 686 Accrued interest 675 683 Accrued payroll and other related expenses 670 877 Accrued bonuses 613 837 Accrued professional fees 492 978 Current operating lease liabilities 238 - Accrued clinical trial costs 127 84 Travel and entertainment 114 280 Accrued sales & use tax 102 259 Other accruals 275 339 Total accrued liabilities $ 4,802 $ 6,766

Note 6 - Note Payable

Note 6 - Note Payable	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	6. Note Payable On May 22, 2017, “2017 $20,000,000 $10,000,000 $30,000,000 December 29, 2017, $10,000,000 A portion of the initial loan proceeds were used to repay all of the amounts owed by the Company under its 2016 2017 may The 2017 six four 2017 12.5%, 4.0% may, three March 31, 2019 2018, $318,000 $305,000, 5.0% March 31, 2019, $573,000 The Company may 2017 first five no As security for its obligations under the 2017 The terms of the 2017 $2.0 2022, not 2.0 2017 March 31, 2019, As of March 31, 2019 December 31, 2018, $30,927,000 $30,528,000, 2017 In connection with the 2017 two 10 222,049 $9.50 9 As of March 31, 2019, Year Ending December 31, 2019 (remaining 9 months) $ 2,103 2020 2,901 2021 16,673 2022 19,306 2023 6,220 Total payments 47,203 Less: Amount representing interest (15,135 ) Present value of obligations 32,068 Less: Unamortized debt discount (1,141 ) Note payable, noncurrent portion $ 30,927

Note 7 - Leases

Note 7 - Leases	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	7. Leases In January 2012, March 2012 April 2018. On February 1, 2017, 12,400 January 26, 2017. June 1, 2017 May 2020. June 2017. The monthly base rent under the Sublease is equal to $20.50 first $21.12 $21.75 second third $22,000. $88,000 Rent expense for the three March 31, 2018 $138,000. In September 2018, 36 September 20, 2018. $3,000. After the adoption of ASU 842 January 1, 2019, 12 not The following table reflects the Company's lease assets and lease liabilities at March 31, 2019 January 1, 2019: March 31, January 1, 2019 2019 Assets: Operating lease right-of-use assets $ 565 $ 629 Liabilities: Current operating lease liabilities $ 238 $ 230 Noncurrent operating lease liabilities 337 399 $ 575 $ 629 The operating lease right-of-use assets are included in other assets on the condensed consolidated balance sheet. The operating lease liabilities are included in accrued liabilities and other noncurrent liabilities on the condensed consolidated balance sheet. The operating leases expense for the three March 31, 2019 $75,000. As of March 31, 2019, Year Ending December 31, 2019 (remaining nine months) $ 222 2020 303 2021 137 Total lease payments 662 Less: Interest (87 ) Present value of lease liabilities $ 575 The weighted average remaining lease term was approximately 26 March 31, 2019. three March 31, 2019 12.5%.

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	8. Commitments and Contingencies Indemnification Agreements The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with performance of services within the scope of the agreement, breach of the agreement by the Company, or noncompliance of regulations or laws by the Company, in all cases provided the indemnified party has not not not Loss Contingencies The Company is or has been subject to proceedings, lawsuits and other claims arising in the ordinary course of business. The Company evaluates contingent liabilities, including threatened or pending litigation, for potential losses. If the potential loss from any claim or legal proceeding is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Because of uncertainties related to these matters, accruals are based upon the best information available. For potential losses for which there is a reasonable possibility (meaning the likelihood is more than remote but less than probable) that a loss exists, the Company will disclose an estimate of the potential loss or range of such potential loss or include a statement that an estimate of the potential loss cannot be made. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may not

Note 9 - Common Stock

Note 9 - Common Stock	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	9. Common Stock March 2019, 27,473 $0.91 $25,000. In December 2018, December 2018 14,728,504 $1.50 $22,093,000. $20,385,000. In June 2018, 100,000 $2.56 $256,000. In February 2018, February 2018 11,500,000 $3.00 $34,500,000. $32,214,000. Through the November 2017 may $25,000,000 three March 31, 2019, zero November 2017 three March 31, 2018, 208,277 November 2017 $1,011,000. March 31, 2019, 336,498 November 2017 $1,318,000. Warrants for Common Stock As of March 31, 2019, Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants September 2014 Common Shares September 23, 2019 $ 4.24 86,831 October 2014 Common Shares October 13, 2019 $ 4.24 29,000 November 2014 Common Shares November 12, 2019 $ 4.24 12,500 February 2015 Common Shares February 17, 2025 $ 4.00 75,697 March 2015 Common Shares March 26, 2025 $ 2.72 1,454 May 2015 Common Shares May 12, 2025 $ 4.24 36,229 May 2015 Common Shares May 17, 2020 $ 4.24 21,585 December 2015 Common Shares December 16, 2025 $ 5.60 26,875 April 2016 Common Shares April 1, 2026 $ 6.08 25,000 May 2016 Common Shares May 11, 2021 $ 7.74 5,000 June 2016 Common Shares June 20, 2026 $ 4.98 100,402 May 2017 Common Shares May 25, 2027 $ 9.50 222,049 642,622 In connection with the 2017 222,049, $9.50 ten $940,000 0%, 55.1%, 2.25% ten $790,000, three March 31, 2019 2018, $83,000 $77,000, No three March 31, 2019 2018. No three March 31, 2019 2018.

Note 10 - Summary of Stock Opti

Note 10 - Summary of Stock Options	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	10 . Summary of Stock Options Stock Option Plans The Company has issued equity awards in the form of stock options and restricted stock awards (“RSAs”) from two 2006 “2006 2013 “2013 As of March 31, 2019, 2006 10,434 no $10.05 3.84 As of March 31, 2019, 2013 5,582,696 678,216 $3.26 8.2 In January 2019, 2019 2013 2,043,142 4,914,016 6,957,158 January 1, 2019. Activity under the 2006 2013 Three Months Ended March 31, 2019 Weighted Weighted Average Number Average Remaining Aggregate of Exercise Contractual Intrinsic Shares Price Term (years) Value Options outstanding, beginning of period 4,014,475 $ 4.56 7.4 $ - Options granted 2,145,000 $ 1.24 Options exercised - Options canceled (566,345 ) $ 4.63 Options outstanding, end of period 5,593,130 $ 3.28 8.2 $ - Vested and exercisable and expected to vest, end of period 5,291,876 $ 3.33 8.1 $ - Vested and exercisable, end of period 1,725,352 $ 5.04 5.6 $ - The aggregate intrinsic value reflects the difference between the exercise price of the underlying stock options and the Company’s closing share price as of March 31, 2019. The options outstanding and exercisable as of March 31, 2019 Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices March 31, 2019 Price Term (Years) March 31, 2019 Price $1.00 - $1.97 2,655,417 $ 1.38 9.67 183,487 $ 1.51 $2.02 - $2.83 97,500 $ 2.42 8.93 12,240 $ 2.64 $3.03 - $3.82 484,376 $ 3.55 8.81 93,126 $ 3.77 $4.30 - $4.97 1,000,954 $ 4.52 7.69 437,550 $ 4.55 $5.01 - $5.67 630,739 $ 5.35 5.98 411,788 $ 5.35 $6.00 - $6.61 463,483 $ 6.02 3.47 415,932 $ 6.02 $7.00 - $7.92 250,227 $ 7.68 6.93 160,795 $ 7.68 $9.92 10,424 $ 9.92 3.85 10,424 $ 9.92 $59.60 - $149.04 10 $ 149.04 2.56 10 $ 149.04 Total: 5,593,130 $ 3.28 8.16 1,725,352 $ 5.04 Restricted Stock Awards (‘RSA”) During the three March 31, 2019, 364,072 2013 2018 2018 50% 50% January 2019. 1,800 March 2019. March 31, 2019, zero As of March 31, 2019, 419,147 2017 The sixth 2017 “2017 January 1, 2019 March 31, 2019, 43,759 March 29, 2019 $0.80. As of March 31, 2019, 2017 212,560 The Company estimates the fair value of purchase rights under the ESPP using a Black-Scholes valuation model. The fair value of each purchase right was estimated on the date of grant using the Black-Scholes option valuation model and the straight-line attribution approach with the following weighted-average assumptions: Three Months Ended March 31, 2019 2018 Expected term (in years) 0.25 0.25 Average volatility 74% 59% Risk-free interest rate 2.45% 1.39% Dividend yield 0% 0% The weighted average grant date fair value of the purchase rights issued under the 2017 three March 31, 2019 2018 $0.33 $1.30, Stock-Based Compensation During the three March 31, 2019 2018, 2,117,500 1,251,171 $1.24 2.77 no three March 31, 2019 2018. The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options granted was estimated using the following weighted average assumptions: Three Months Ended March 31, 2019 2018 Expected term (in years) 5 5 Average volatility 73% 76% Risk-free interest rate 2.53% 2.48% Dividend yield 0% 0% During the three March 31, 2019 2018, 27,500 2,388 $1.22 $2.98, no three March 31, 2019 2018. The fair value of nonemployee stock options granted was estimated using the following weighted average assumptions: Three Months Ended March 31, 2019 2018 Expected term (in years) 5 10 Average volatility 73% 77% Risk-free interest rate 2.49% 2.73% Dividend yield 0% 0% Option-pricing models require the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. The expected stock price volatility is based on analysis of the Company’s stock price history over a period commensurate with the expected term of the options, trading volume of comparable companies’ stock, look-back volatilities and the Company specific events that affected volatility in a prior period. The expected term of employee stock options represents the weighted average period the stock options are expected to remain outstanding and is based on the history of exercises and cancellations on all past option grants made by the Company, the contractual term, the vesting period and the expected remaining term of the outstanding options. The risk-free interest rate is based on the U.S. Treasury interest rates whose term is consistent with the expected life of the stock options. No not not The following table shows stock-based compensation expense included in the condensed consolidated statements of operations for the three March 31, 2019 2018 Three Months Ended March 31, 2019 2018 Cost of revenue $ 32 $ 11 Research and development 40 122 Selling, general and administrative 424 620 Total $ 496 $ 753 As of March 31, 2019, $4,607,000. 2.6

Note 11 - Income Taxes

Note 11 - Income Taxes	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Income Tax Disclosure [Text Block]	11 . Income Taxes No no For interim periods, the Company estimates its annual effective income tax rate and applies the estimated rate to the year-to-date income or loss before income taxes. The Company also computes the tax provision or benefit related to items reported separately and recognizes the items net of their related tax effect in the interim periods in which they occur. The Company also recognizes the effect of changes in enacted tax laws or rates in the interim periods in which the changes occur. The Company’s effective tax rate is 0% three March 31, 2019 March 31, 2018. 2019 0%.

Note 12 - Related Party Transac

Note 12 - Related Party Transactions	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	12 . Related Party Transactions In June 2006, October 4, 2007. 300 March 31, 2019, 809 37,500 $1,489,000 $3,273,000 three March 31, 2019 2018, March 31, 2019 December 31, 2018 $619,000 $960,000,

Note 13 - Restructuring Costs

Note 13 - Restructuring Costs	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Restructuring and Related Activities Disclosure [Text Block]	1 3 . Restructuring Costs In January 2019, 40 $742,000 March 31, 2019, $24,000 June 30, 2019. first 2019

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Financial Statement Presentation The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may
Changes in Accounting Policies, Policy [Policy Text Block]	Changes in Accounting Policies Except for the changes for the adoption of the new revenue recognition accounting standard, the Company has consistently applied the accounting policies to all periods presented in these condensed consolidated financial statements. Adoption of New Accounting Standard - Leases The Company adopted FASB’s Accounting Standards Update (“ASU”) No. 2016 02, 842 January 1, 2019, $629,000 $629,000, January 1, 2019. not not The effect of the changes made to our consolidated January 1, 2019 Adjustments Due to December 31, Adoption of January 1, 2018 ASC 842 2019 Other assets $ 171 $ 629 (1) $ 800 Total assets $ 46,834 $ 629 (1) $ 47,463 Accrued liabilities $ 6,766 $ 230 (2) $ 6,996 Total current liabilities $ 10,760 $ 230 (2) $ 10,990 Other noncurrent liabilities $ 634 $ 399 (2) $ 1,033 Total liabilities $ 41,922 $ 629 (2) $ 42,551 Total liabilities and stockholders' equity $ 46,834 $ 629 (2) $ 47,463 ( 1 Represents capitalization of operating lease right-of-use assets and reclassification of deferred rent. ( 2 Represents recognition of operating lease liabilities.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three one may,
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no Most of the Company’s products to date require clearance or approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device that it refers to as the Viveve System, which is intended for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, for use in general surgical procedures for electrocoagulation and hemostasis, and stress urinary incontinence, depending on the relevant country-specific clearance or approval. The Viveve System consists of three four five third In North America, the Company sells its products primarily through a direct sales force to health care practitioners. Outside North America, the Company sells through an extensive network of distribution partners. During the three March 31, 2019, three 42% three March 31, 2018, two 54% no 10% three March 31, 2019 2018. As of March 31, 2019, four 62% December 31, 2018, three 54%
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not six may six not $395,000 March 31, 2019 $284,000 December 31, 2018.
Revenue [Policy Text Block]	Revenue Recognition Revenue consists primarily of the sale of the Viveve System, single-use treatment tips and ancillary consumables. The Company applies the following five 1 2 3 4 5 Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance for differing indications, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. In North America, we market and sell primarily through a direct sales force. Outside of North America, we market and sell primarily through distribution partners. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Contract Assets and Liabilities The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No March 31, 2019 December 31, 2018. $679,000, not March 31, 2019 $686,000 December 31, 2018. The following table reflects the changes in our customer contract liabilities for the three March 31, 2019: March 31, December 31, Three Months 2019 2018 Change Customer contracts liabilities: Marketing programs $ 627 $ 639 $ (12 ) Other 52 47 5 Total $ 679 $ 686 $ (7 ) Separately, accounts receivable, net represents receivables from contracts with customers. Significant Financing Component The Company applies the practical expedient to not not one three March 31, 2019 2018, not Contract Costs The Company has elected the practical expedient to recognize the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that the Company otherwise would have recognized is one three March 31, 2019 2018, one Shipping and Handling Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. Revenue by Geographic Area Management has determined that the sales by geography is a key indicator for understanding the Company’s financials because of the different sales and business models that are required in the various regions of the world (including regulatory, selling channels, pricing, customers and marketing efforts). The following table presents the revenue from unaffiliated customers disaggregated by geographic area for the three March 31, 2019 2018 Three Months Ended March 31, 2019 2018 North America $ 1,792 $ 2,606 Asia Pacific 967 891 Europe and Middle East 246 202 Latin America 7 - Total $ 3,012 $ 3,699 The Company determines geographic location of its revenue based upon the destination of the shipments of its products.
Equity Method Investments [Policy Text Block]	Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not 1 2 3 three not The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee’s business segment might indicate a loss in value. The carrying value of the investments is reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not No three March 31, 2019 2018.
Standard Product Warranty, Policy [Policy Text Block]	Product Warranty The Company’s products are generally subject to warranties between one three not
Share-based Payment Arrangement [Policy Text Block]	Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee’s service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. The Company determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option’s expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded at their fair value on the measurement date and are subject to periodic adjustment as the underlying equity instruments vest.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may three March 31, 2019 2018,
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. Three Months Ended March 31, 2019 2018 Stock options to purchase common stock 5,593,130 3,690,902 Warrants to purchase common stock 642,622 642,622 Restricted common stock awards 419,147 22,500
New Accounting Pronouncements, Policy [Policy Text Block]	Other Recently Issued and Adopted Accounting Standards In June 2018, 2018 07, 718 718 718 December 15, 2018, January 1, 2019 not We have reviewed other recent accounting pronouncements and concluded they are either not no

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Cumulative Effect of Adjustments for New Accounting Pronouncements on Balance Sheet [Table Text Block]	Adjustments Due to December 31, Adoption of January 1, 2018 ASC 842 2019 Other assets $ 171 $ 629 (1) $ 800 Total assets $ 46,834 $ 629 (1) $ 47,463 Accrued liabilities $ 6,766 $ 230 (2) $ 6,996 Total current liabilities $ 10,760 $ 230 (2) $ 10,990 Other noncurrent liabilities $ 634 $ 399 (2) $ 1,033 Total liabilities $ 41,922 $ 629 (2) $ 42,551 Total liabilities and stockholders' equity $ 46,834 $ 629 (2) $ 47,463
Contract with Customer, Asset and Liability [Table Text Block]	March 31, December 31, Three Months 2019 2018 Change Customer contracts liabilities: Marketing programs $ 627 $ 639 $ (12 ) Other 52 47 5 Total $ 679 $ 686 $ (7 )
Revenue from External Customers by Geographic Areas [Table Text Block]	Three Months Ended March 31, 2019 2018 North America $ 1,792 $ 2,606 Asia Pacific 967 891 Europe and Middle East 246 202 Latin America 7 - Total $ 3,012 $ 3,699
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended March 31, 2019 2018 Stock options to purchase common stock 5,593,130 3,690,902 Warrants to purchase common stock 642,622 642,622 Restricted common stock awards 419,147 22,500

Note 5 - Accrued Liabilities (T

Note 5 - Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	March 31, December 31, 2019 2018 Accrued sales commission $ 817 $ 1,743 Customer contracts liabilities 679 686 Accrued interest 675 683 Accrued payroll and other related expenses 670 877 Accrued bonuses 613 837 Accrued professional fees 492 978 Current operating lease liabilities 238 - Accrued clinical trial costs 127 84 Travel and entertainment 114 280 Accrued sales & use tax 102 259 Other accruals 275 339 Total accrued liabilities $ 4,802 $ 6,766

Note 6 - Note Payable (Tables)

Note 6 - Note Payable (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Debt [Table Text Block]	Year Ending December 31, 2019 (remaining 9 months) $ 2,103 2020 2,901 2021 16,673 2022 19,306 2023 6,220 Total payments 47,203 Less: Amount representing interest (15,135 ) Present value of obligations 32,068 Less: Unamortized debt discount (1,141 ) Note payable, noncurrent portion $ 30,927

Note 7 - Leases (Tables)

Note 7 - Leases (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Lessee, Lease Assets and Liabilities [Table Text Block]	March 31, January 1, 2019 2019 Assets: Operating lease right-of-use assets $ 565 $ 629 Liabilities: Current operating lease liabilities $ 238 $ 230 Noncurrent operating lease liabilities 337 399 $ 575 $ 629
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Year Ending December 31, 2019 (remaining nine months) $ 222 2020 303 2021 137 Total lease payments 662 Less: Interest (87 ) Present value of lease liabilities $ 575

Note 9 - Common Stock (Tables)

Note 9 - Common Stock (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants September 2014 Common Shares September 23, 2019 $ 4.24 86,831 October 2014 Common Shares October 13, 2019 $ 4.24 29,000 November 2014 Common Shares November 12, 2019 $ 4.24 12,500 February 2015 Common Shares February 17, 2025 $ 4.00 75,697 March 2015 Common Shares March 26, 2025 $ 2.72 1,454 May 2015 Common Shares May 12, 2025 $ 4.24 36,229 May 2015 Common Shares May 17, 2020 $ 4.24 21,585 December 2015 Common Shares December 16, 2025 $ 5.60 26,875 April 2016 Common Shares April 1, 2026 $ 6.08 25,000 May 2016 Common Shares May 11, 2021 $ 7.74 5,000 June 2016 Common Shares June 20, 2026 $ 4.98 100,402 May 2017 Common Shares May 25, 2027 $ 9.50 222,049 642,622

Note 10 - Summary of Stock Op_2

Note 10 - Summary of Stock Options (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Three Months Ended March 31, 2019 Weighted Weighted Average Number Average Remaining Aggregate of Exercise Contractual Intrinsic Shares Price Term (years) Value Options outstanding, beginning of period 4,014,475 $ 4.56 7.4 $ - Options granted 2,145,000 $ 1.24 Options exercised - Options canceled (566,345 ) $ 4.63 Options outstanding, end of period 5,593,130 $ 3.28 8.2 $ - Vested and exercisable and expected to vest, end of period 5,291,876 $ 3.33 8.1 $ - Vested and exercisable, end of period 1,725,352 $ 5.04 5.6 $ -
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices March 31, 2019 Price Term (Years) March 31, 2019 Price $1.00 - $1.97 2,655,417 $ 1.38 9.67 183,487 $ 1.51 $2.02 - $2.83 97,500 $ 2.42 8.93 12,240 $ 2.64 $3.03 - $3.82 484,376 $ 3.55 8.81 93,126 $ 3.77 $4.30 - $4.97 1,000,954 $ 4.52 7.69 437,550 $ 4.55 $5.01 - $5.67 630,739 $ 5.35 5.98 411,788 $ 5.35 $6.00 - $6.61 463,483 $ 6.02 3.47 415,932 $ 6.02 $7.00 - $7.92 250,227 $ 7.68 6.93 160,795 $ 7.68 $9.92 10,424 $ 9.92 3.85 10,424 $ 9.92 $59.60 - $149.04 10 $ 149.04 2.56 10 $ 149.04 Total: 5,593,130 $ 3.28 8.16 1,725,352 $ 5.04
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three Months Ended March 31, 2019 2018 Expected term (in years) 5 5 Average volatility 73% 76% Risk-free interest rate 2.53% 2.48% Dividend yield 0% 0% Three Months Ended March 31, 2019 2018 Expected term (in years) 5 10 Average volatility 73% 77% Risk-free interest rate 2.49% 2.73% Dividend yield 0% 0%
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended March 31, 2019 2018 Cost of revenue $ 32 $ 11 Research and development 40 122 Selling, general and administrative 424 620 Total $ 496 $ 753
2017 Employee Stock Purchase Plan [Member]
Notes Tables
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]	Three Months Ended March 31, 2019 2018 Expected term (in years) 0.25 0.25 Average volatility 74% 59% Risk-free interest rate 2.45% 1.39% Dividend yield 0% 0%

Note 1 - The Company and Basi_2

Note 1 - The Company and Basis of Presentation (Details Textual) - USD ($)	Feb. 12, 2018	Nov. 08, 2017	Dec. 31, 2018	Feb. 28, 2018	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Jun. 08, 2018	Dec. 31, 2017
Shares Issued, Price Per Share					$ 0.91		$ 0.91	$ 2.56
Proceeds from Issuance of Common Stock						$ 33,236,000
Retained Earnings (Accumulated Deficit), Ending Balance			$ (155,385,000)		(165,414,000)		$ (165,414,000)
Cash and Cash Equivalents, at Carrying Value, Ending Balance			$ 29,523,000		17,821,000	38,378,000	17,821,000		$ 20,730,000
Working Capital					22,095,000		$ 22,095,000
Net Cash Provided by (Used in) Operating Activities, Total					$ (11,558,000)	$ (15,191,000)
December 2018 Offering [Member]
Stock Issued During Period, Shares, New Issues			14,728,504
Shares Issued, Price Per Share			$ 1.50
Proceeds from Issuance of Common Stock			$ 22,093,000
Proceeds From Issuance of Common Stock, Net			$ 20,385,000
February 2018 Offering [Member]
Stock Issued During Period, Shares, New Issues	11,500,000			11,500,000
Shares Issued, Price Per Share	$ 3			$ 3
Proceeds from Issuance of Common Stock	$ 34,500,000			$ 34,500,000
Proceeds From Issuance of Common Stock, Net	$ 32,214,000			$ 32,214,000
November 2017 ATM Facility [Member]
Stock Issued During Period, Shares, New Issues					0	208,277	336,498
Proceeds From Issuance of Common Stock, Net						$ 1,011,000	$ 1,318,000
Aggregate Offering Price		$ 25,000,000

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual)	3 Months Ended		12 Months Ended
	Mar. 31, 2019USD ($)	Mar. 31, 2018USD ($)	Dec. 31, 2018USD ($)	Jan. 01, 2019USD ($)
Operating Lease, Right-of-Use Asset	$ 565,000			$ 629,000
Operating Lease, Liability, Total	$ 575,000			$ 629,000
Number of Financial Institutions	1
Accounts Receivable, Allowance for Credit Loss, Ending Balance	$ 395,000		$ 284,000
Contract with Customer, Asset, after Allowance for Credit Loss, Total	0		0
Contract with Customer, Liability, Total	$ 679,000		$ 686,000
Equity Method Investment, Other than Temporary Impairment		$ 0
Minimum [Member]
Warranty Period	1 year
Maximum [Member]
Warranty Period	3 years
Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Concentration Risk, Number of Customers	3	2
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Three Customers [Member]
Concentration Risk, Percentage	42.00%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Two Customers [Member]
Concentration Risk, Percentage		54.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Number of Customers	4		3
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Three Customers [Member]
Concentration Risk, Percentage			54.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Four Customers [Member]
Concentration Risk, Percentage	62.00%

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Cumulative Effect of Adjustments for New Accounting Pronouncements on Consolidated Balance Sheet (Details) - USD ($) $ in Thousands		Mar. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Other assets		$ 719	$ 800	$ 171
Total assets		34,852	47,463	46,834
Accrued liabilities		4,802	6,996	6,766
Total current liabilities		7,488	10,990	10,760
Other noncurrent liabilities		1,023	1,033	634
Total liabilities		39,438	42,551	41,922
Total liabilities and stockholders' equity		$ 34,852	47,463	$ 46,834
Accounting Standards Update 2016-02 [Member]
Other assets	[1]		629
Total assets	[1]		629
Accrued liabilities	[2]		230
Total current liabilities	[2]		230
Other noncurrent liabilities	[2]		399
Total liabilities	[2]		629
Total liabilities and stockholders' equity	[2]		$ 629
[1]	Represents capitalization of operating lease right-of-use assets and reclassification of deferred rent.
[2]	Represents recognition of operating lease liabilities.

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Customer Contract Liabilities (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Customer contract liabilities	$ 679,000	$ 686,000
Change in customer contract liabilities	(7,000)
Marketing Programs [Member]
Customer contract liabilities	627,000	639,000
Change in customer contract liabilities	(12,000)
Product and Service, Other [Member]
Customer contract liabilities	52,000	$ 47,000
Change in customer contract liabilities	$ 5,000

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Revenue From Unaffiliated Customers by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenue	$ 3,012	$ 3,699
North America [Member]
Revenue	1,792	2,606
Asia Pacific [Member]
Revenue	967	891
Europe And Middle East [Member]
Revenue	246	202
Latin America [Member]
Revenue	$ 7

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Payment Arrangement, Option [Member]
Stock options to purchase common stock (in shares)	5,593,130	3,690,902
Common Stock Warrants [Member]
Stock options to purchase common stock (in shares)	642,622	642,622
Restricted Stock [Member]
Stock options to purchase common stock (in shares)	419,147	22,500

Note 4 - Investment in Limite_2

Note 4 - Investment in Limited Liability Company (Details Textual)	Aug. 08, 2017USD ($)	Mar. 31, 2019USD ($)	Mar. 31, 2018USD ($)	Dec. 31, 2018USD ($)
Income (Loss) from Equity Method Investments, Total		$ (125,000)	$ (249,000)
Membership Unit Subscription Agreement [Member] | InControl Medical [Member]
Accounts Payable, Related Parties, Current		$ 0		$ 0
InControl Medical [Member]
Equity Method Investment, Ownership Percentage		9.00%
Income (Loss) from Equity Method Investments, Total		$ 125,000
InControl Medical [Member] | Membership Unit Subscription Agreement [Member]
Unrecorded Unconditional Purchase Obligation, Period Quantity Purchased		4,800
Payments for Purchase of Products		$ 27,000
Payments to Acquire Equity Method Investments	$ 2,500,000

Note 5 - Accrued Liabilities -

Note 5 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Accrued sales commission	$ 817		$ 1,743
Customer contracts liabilities	679		686
Accrued interest	675		683
Accrued payroll and other related expenses	670		877
Accrued bonuses	613		837
Accrued professional fees	492		978
Current operating lease liabilities	238	$ 230
Accrued clinical trial costs	127		84
Travel and entertainment	114		280
Accrued sales & use tax	102		259
Other accruals	275		339
Total accrued liabilities	$ 4,802	$ 6,996	$ 6,766

Note 6 - Note Payable (Details

Note 6 - Note Payable (Details Textual) - USD ($)	May 22, 2017	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Interest Payable		$ 15,135,000
Notes Payable, Noncurrent, Total		$ 30,927,000		$ 30,528,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		642,622
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Warrants and Rights Outstanding, Term	10 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	222,049	222,049
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 9.50	$ 9.50
The 2017 Loan Agreement [Member] | CRG LP [Member]
Debt Instrument, Face Amount	$ 20,000,000
Debt Agreement, Covenant, Additional Funding	10,000,000
Debt Agreement, Maximum Borrowing Capacity	$ 30,000,000
Debt Instrument, Term	6 years
Debt instrument, Interest Only Payment, Period	4 years
Debt Instrument, Interest Rate, Stated Percentage	12.50%
Debt Instrument, Interest Rate, Stated Percentage Deferred During Interest-only Period	4.00%
Paid-in-Kind Interest		$ 318,000	$ 305,000
Debt Instrument, Prepayment Fee, Percentage	5.00%
Debt Instrument, Prepayment Fee, Period of Term	5 years
Debt Instrument, Covenant, Cash and Cash Equivalents	$ 2,000,000
Notes Payable, Noncurrent, Total		30,927,000		$ 30,528,000
The 2017 Loan Agreement [Member] | CRG LP [Member] | Other Noncurrent Liabilities [Member]
Interest Payable		$ 573,000

Note 6 - Note Payable - Summary

Note 6 - Note Payable - Summary of Note Payable (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
2019 (remaining 9 months)	$ 2,103
2020	2,901
2021	16,673
2022	19,306
2023	6,220
Total payments	47,203
Less: Amount representing interest	(15,135)
Present value of obligations	32,068
Less: Unamortized debt discount	(1,141)
Note payable, noncurrent portion	$ 30,927	$ 30,528

Note 7 - Leases (Details Textua

Note 7 - Leases (Details Textual)	1 Months Ended	3 Months Ended
	Sep. 30, 2018USD ($)	Mar. 31, 2019USD ($)	Mar. 31, 2018USD ($)	Feb. 01, 2017USD ($)ft²
Operating Leases, Rent Expense, Total			$ 138,000
Operating Lease, Cost		$ 75,000
Operating Lease, Weighted Average Remaining Lease Term		2 years 60 days
Operating Lease, Weighted Average Discount Rate, Percent		12.50%
Sublease Agreement for Relocation of Headquarters [Member]
Area of Real Estate Property | ft²				12,400
Operating Leases, Monthly Rent Per Rentable Square Foot During First Year				20.5
Operating Leases, Monthly Rent Per Rentable Square Foot During Second Year				21.12
Operating Leases, Monthly Rent Per Rentable Square Foot During Third Year				21.75
Security Deposit				$ 22,000
Operating Leases, Allowance for Certain Improvements				$ 88,000
Noncancelable Operating Lease Agreement for Office Equipment [Member]
Lessee, Operating Lease, Term of Contract	3 years
Operating Leases, Monthly Payment	$ 3,000

Note 7 - Leases - Lease Assets

Note 7 - Leases - Lease Assets and Liabilities (Details) - USD ($)	Mar. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Operating Lease, Right-of-Use Asset	$ 565,000	$ 629,000
Current operating lease liabilities	238,000	230,000
Noncurrent operating lease liabilities	337,000	399,000
	$ 575,000	$ 629,000

Note 7 - Leases - Maturity of O

Note 7 - Leases - Maturity of Operating Lease Liabilities (Details) - USD ($)	Mar. 31, 2019	Jan. 01, 2019
2019 (remaining nine months)	$ 222,000
2020	303,000
2021	137,000
Total lease payments	662,000
Less: Interest	(87,000)
Present value of lease liabilities	$ 575,000	$ 629,000

Note 9 - Common Stock (Details

Note 9 - Common Stock (Details Textual)	Jun. 08, 2018USD ($)$ / sharesshares	Feb. 12, 2018USD ($)$ / sharesshares	Nov. 08, 2017USD ($)	Mar. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares	Feb. 28, 2018USD ($)$ / sharesshares	Mar. 31, 2019USD ($)$ / sharesshares	Mar. 31, 2018USD ($)shares	Mar. 31, 2019USD ($)$ / sharesshares	May 22, 2017USD ($)yr$ / sharesshares
Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares	100,000			27,473
Shares Issued, Price Per Share | $ / shares	$ 2.56			$ 0.91			$ 0.91		$ 0.91
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 256,000			$ 25,000			$ 25,000	$ 108,000
Proceeds from Issuance of Common Stock								$ 33,236,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares				642,622			642,622		642,622
Class of Warrants or Rights, Exercises in Period | shares							0	0
Class of Warrant or Right Number of Securities Called by Warrants or Rights Cancelled In Period | shares							0	0
Share-based Payment Arrangement, Expense							$ 496,000	$ 753,000
The 2017 Loan Agreement [Member]
Debt Issuance Costs, Net, Total				$ 790,000			790,000		$ 790,000
Amortization of Debt Discount (Premium)							$ 83,000	77,000
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares				222,049			222,049		222,049	222,049
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 9.50			$ 9.50		$ 9.50	$ 9.50
Warrants and Rights Outstanding, Term										10 years
Warrants and Rights Outstanding										$ 940,000
Share-based Payment Arrangement, Expense								$ 0
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input										0
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input										0.551
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input										0.0225
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input | yr										10
December 2018 Offering [Member]
Shares Issued, Price Per Share | $ / shares					$ 1.50
Stock Issued During Period, Shares, New Issues | shares					14,728,504
Proceeds from Issuance of Common Stock					$ 22,093,000
Proceeds From Issuance of Common Stock, Net					$ 20,385,000
February 2018 Offering [Member]
Shares Issued, Price Per Share | $ / shares		$ 3				$ 3
Stock Issued During Period, Shares, New Issues | shares		11,500,000				11,500,000
Proceeds from Issuance of Common Stock		$ 34,500,000				$ 34,500,000
Proceeds From Issuance of Common Stock, Net		$ 32,214,000				$ 32,214,000
November 2017 ATM Facility [Member]
Stock Issued During Period, Shares, New Issues | shares							0	208,277	336,498
Proceeds From Issuance of Common Stock, Net								$ 1,011,000	$ 1,318,000
Aggregate Offering Price			$ 25,000,000

Note 9 - Common Stock - Summary

Note 9 - Common Stock - Summary of Outstanding Warrants (Details) - $ / shares	3 Months Ended
	Mar. 31, 2019	May 22, 2017
Shares Outstanding Under Warrants (in shares)	642,622
September 2014 Issuance Through Private Offering [Member]
Expiration Date	Sep. 23, 2019
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	86,831
Vendors and Contractor Warrants, October 2014 Issuance [Member]
Expiration Date	Oct. 13, 2019
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	29,000
Vendors and Contractor Warrants, November 2014 Issuance [Member]
Expiration Date	Nov. 12, 2019
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	12,500
Employee Performance Bonus Warrants, February 2015 Issuance [Member]
Expiration Date	Feb. 17, 2025
Exercise Price (in dollars per share)	$ 4
Shares Outstanding Under Warrants (in shares)	75,697
Contractor Warrants, March 2015 Issuance [Member]
Expiration Date	Mar. 26, 2025
Exercise Price (in dollars per share)	$ 2.72
Shares Outstanding Under Warrants (in shares)	1,454
Contractor Warrants, May 2015 Issuance [Member]
Expiration Date	May 12, 2025
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	36,229
May 2015 Issuance Second Contractor [Member]
Expiration Date	May 17, 2020
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	21,585
Performance Bonus Warrants, December 2015 Issuance [Member]
Expiration Date	Dec. 16, 2025
Exercise Price (in dollars per share)	$ 5.60
Shares Outstanding Under Warrants (in shares)	26,875
Distributor Warrants, April 2016 Issuance [Member]
Expiration Date	Apr. 1, 2026
Exercise Price (in dollars per share)	$ 6.08
Shares Outstanding Under Warrants (in shares)	25,000
Contractor Warrants, May 2016 Issuance [Member]
Expiration Date	May 11, 2021
Exercise Price (in dollars per share)	$ 7.74
Shares Outstanding Under Warrants (in shares)	5,000
June 2016 Issuance Related to 2016 Loan Agreement [Member]
Expiration Date	Jun. 20, 2026
Exercise Price (in dollars per share)	$ 4.98
Shares Outstanding Under Warrants (in shares)	100,402
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Expiration Date	May 25, 2027
Exercise Price (in dollars per share)	$ 9.50	$ 9.50
Shares Outstanding Under Warrants (in shares)	222,049	222,049

Note 10 - Summary of Stock Op_3

Note 10 - Summary of Stock Options (Details Textual) - USD ($)	Mar. 29, 2019	Jan. 01, 2019	Mar. 31, 2019	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Jun. 08, 2018	Dec. 06, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance			5,593,130	5,593,130		4,014,475
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance			$ 3.28	$ 3.28		$ 4.56
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term				8 years 73 days		7 years 146 days
Shares Issued, Price Per Share			$ 0.91	$ 0.91			$ 2.56
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				2,145,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate				0.00%	0.00%
Nonemployees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate				0.00%	0.00%
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period			1,800
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period				0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance			419,147	419,147
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate				0.00%
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount			$ 4,607,000	$ 4,607,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition				2 years 219 days
The 2006 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance			10,434	10,434
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance			$ 10.05	$ 10.05
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term				3 years 306 days
The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance			5,582,696	5,582,696
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance			$ 3.26	$ 3.26
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term				8 years 73 days
Common Stock, Capital Shares Reserved for Future Issuance			678,216	678,216
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized		2,043,142
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		6,957,158						4,914,016
The 2013 Plan [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				2,117,500	1,251,171
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value				$ 1.24	$ 2.77
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period					0	0
The 2013 Plan [Member] | Nonemployees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				27,500	2,388
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value				$ 1.22	$ 2.98
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period				0	0
The 2013 Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				364,072
2017 Employee Stock Purchase Plan [Member]
Stock Issued During Period, Shares, Employee Stock Purchase Plans	43,759
Employee Stock Purchase Plan, Purchase Price	$ 0.80
Employee Stock Ownership Plan (ESOP), Number of Suspense Shares			212,560	212,560
Shares Issued, Price Per Share			$ 0.33	$ 0.33	$ 1.30
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate				0.00%	0.00%

Note 10 - Summary of Stock Op_4

Note 10 - Summary of Stock Options - Summary of Option Activity Under All Plans (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Options outstanding (in shares)	4,014,475
Options outstanding, weighted average exercise price (in dollars per share)	$ 4.56
Options outstanding, weighted average remaining contractual term (Year)	8 years 73 days	7 years 146 days
Options granted (in shares)	2,145,000
Options granted, weighted average exercise price (in dollars per share)	$ 1.24
Options exercised (in shares)
Options exercised, weighted average exercise price (in dollars per share)
Options canceled (in shares)	(566,345)
Options canceled, weighted average exercise price (in dollars per share)	$ 4.63
Options outstanding (in shares)	5,593,130	4,014,475
Options outstanding, weighted average exercise price (in dollars per share)	$ 3.28	$ 4.56
Options outstanding, aggregate intrinsic value
Vested and exercisable and expected to vest, end of period (in shares)	5,291,876
Vested and exercisable and expected to vest, end of period, weighted average exercise price (in dollars per share)	$ 3.33
Vested and exercisable and expected to vest, end of period, weighted average remaining contractual term (Year)	8 years 36 days
Vested and exercisable and expected to vest, end of period, aggregate intrinsic value
Vested and exercisable, end of period (in shares)	1,725,352
Vested and exercisable, end of period, weighted average exercise price (in dollars per share)	$ 5.04
Vested and exercisable, end of period, weighted average remaining contractual term (Year)	5 years 219 days
Vested and exercisable, end of period, aggregate intrinsic value

Note 10 - Summary of Stock Op_5

Note 10 - Summary of Stock Options - Summary of Options Outstanding and Exercisable (Details)	3 Months Ended
	Mar. 31, 2019$ / sharesshares
Options outstanding, number (in shares) | shares	5,593,130
Options outstanding, weighted average exercise price (in dollars per share)	$ 3.28
Options outstanding, weighted average remaining contractual term (Year)	8 years 58 days
Options exercisable, number exercisable (in shares) | shares	1,725,352
Options exercisable, weighted average exercise price (in dollars per share)	$ 5.04
Range One [Member]
Exercise price range, lower limit (in dollars per share)	1
Exercise price range, upper limit (in dollars per share)	$ 1.97
Options outstanding, number (in shares) | shares	2,655,417
Options outstanding, weighted average exercise price (in dollars per share)	$ 1.38
Options outstanding, weighted average remaining contractual term (Year)	9 years 244 days
Options exercisable, number exercisable (in shares) | shares	183,487
Options exercisable, weighted average exercise price (in dollars per share)	$ 1.51
Range Two [Member]
Exercise price range, lower limit (in dollars per share)	2.02
Exercise price range, upper limit (in dollars per share)	$ 2.83
Options outstanding, number (in shares) | shares	97,500
Options outstanding, weighted average exercise price (in dollars per share)	$ 2.42
Options outstanding, weighted average remaining contractual term (Year)	8 years 339 days
Options exercisable, number exercisable (in shares) | shares	12,240
Options exercisable, weighted average exercise price (in dollars per share)	$ 2.64
Range Three [Member]
Exercise price range, lower limit (in dollars per share)	3.03
Exercise price range, upper limit (in dollars per share)	$ 3.82
Options outstanding, number (in shares) | shares	484,376
Options outstanding, weighted average exercise price (in dollars per share)	$ 3.55
Options outstanding, weighted average remaining contractual term (Year)	8 years 295 days
Options exercisable, number exercisable (in shares) | shares	93,126
Options exercisable, weighted average exercise price (in dollars per share)	$ 3.77
Range Four [Member]
Exercise price range, lower limit (in dollars per share)	4.30
Exercise price range, upper limit (in dollars per share)	$ 4.97
Options outstanding, number (in shares) | shares	1,000,954
Options outstanding, weighted average exercise price (in dollars per share)	$ 4.52
Options outstanding, weighted average remaining contractual term (Year)	7 years 251 days
Options exercisable, number exercisable (in shares) | shares	437,550
Options exercisable, weighted average exercise price (in dollars per share)	$ 4.55
Range Five [Member]
Exercise price range, lower limit (in dollars per share)	5.01
Exercise price range, upper limit (in dollars per share)	$ 5.67
Options outstanding, number (in shares) | shares	630,739
Options outstanding, weighted average exercise price (in dollars per share)	$ 5.35
Options outstanding, weighted average remaining contractual term (Year)	5 years 357 days
Options exercisable, number exercisable (in shares) | shares	411,788
Options exercisable, weighted average exercise price (in dollars per share)	$ 5.35
Range Six [Member]
Exercise price range, lower limit (in dollars per share)	6
Exercise price range, upper limit (in dollars per share)	$ 6.61
Options outstanding, number (in shares) | shares	463,483
Options outstanding, weighted average exercise price (in dollars per share)	$ 6.02
Options outstanding, weighted average remaining contractual term (Year)	3 years 171 days
Options exercisable, number exercisable (in shares) | shares	415,932
Options exercisable, weighted average exercise price (in dollars per share)	$ 6.02
Range Seven [Member]
Exercise price range, lower limit (in dollars per share)	7
Exercise price range, upper limit (in dollars per share)	$ 7.92
Options outstanding, number (in shares) | shares	250,227
Options outstanding, weighted average exercise price (in dollars per share)	$ 7.68
Options outstanding, weighted average remaining contractual term (Year)	6 years 339 days
Options exercisable, number exercisable (in shares) | shares	160,795
Options exercisable, weighted average exercise price (in dollars per share)	$ 7.68
Range Eight [Member]
Exercise price range, lower limit (in dollars per share)	9.92
Exercise price range, upper limit (in dollars per share)	$ 9.92
Options outstanding, number (in shares) | shares	10,424
Options outstanding, weighted average exercise price (in dollars per share)	$ 9.92
Options outstanding, weighted average remaining contractual term (Year)	3 years 310 days
Options exercisable, number exercisable (in shares) | shares	10,424
Options exercisable, weighted average exercise price (in dollars per share)	$ 9.92
Range Nine [Member]
Exercise price range, lower limit (in dollars per share)	59.60
Exercise price range, upper limit (in dollars per share)	$ 149.04
Options outstanding, number (in shares) | shares	10
Options outstanding, weighted average exercise price (in dollars per share)	$ 149.04
Options outstanding, weighted average remaining contractual term (Year)	2 years 204 days
Options exercisable, number exercisable (in shares) | shares	10
Options exercisable, weighted average exercise price (in dollars per share)	$ 149.04

Note 10 - Summary of Stock Op_6

Note 10 - Summary of Stock Options - Valuation Assumption for Employee Stock Purchase Plan (Details)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Expected term (Year)	5 years	5 years
Average volatility	73.00%	76.00%
Risk-free interest rate	2.53%	2.48%
Dividend yield	0.00%	0.00%
2017 Employee Stock Purchase Plan [Member]
Expected term (Year)	91 days	91 days
Average volatility	74.00%	59.00%
Risk-free interest rate	2.45%	1.39%
Dividend yield	0.00%	0.00%

Note 10 - Summary of Stock Op_7

Note 10 - Summary of Stock Options - Valuation Assumptions for Stock Options (Details)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Expected term (Year)	5 years	5 years
Average volatility	73.00%	76.00%
Risk-free interest rate	2.53%	2.48%
Dividend yield	0.00%	0.00%
Nonemployees [Member]
Expected term (Year)	5 years	10 years
Average volatility	73.00%	77.00%
Risk-free interest rate	2.49%	2.73%
Dividend yield	0.00%	0.00%

Note 10 - Summary of Stock Op_8

Note 10 - Summary of Stock Options - Stock-based Compensation Expense Included in the Statement of Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Stock-based compensation expense	$ 496	$ 753
Cost of Sales [Member]
Stock-based compensation expense	32	11
Research and Development Expense [Member]
Stock-based compensation expense	40	122
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense	$ 424	$ 620

Note 11 - Income Taxes (Details

Note 11 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2019
Income Tax Expense (Benefit), Total	$ 0
Effective Income Tax Rate Reconciliation, Percent, Total	0.00%	0.00%
Forecast [Member]
Effective Income Tax Rate Reconciliation, Percent, Total			0.00%

Note 12 - Related Party Trans_2

Note 12 - Related Party Transactions (Details Textual) - Stellartech Research Corporation [Member] - USD ($)	3 Months Ended		135 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Stock Issued During Period, Shares, New Issues			37,500
Related Party Transaction, Amounts of Transaction	$ 1,489,000	$ 3,273,000
Accounts Payable, Related Parties, Current	$ 619,000		$ 960,000

Note 13 - Restructuring Costs (

Note 13 - Restructuring Costs (Details Textual)	1 Months Ended	3 Months Ended
	Jan. 31, 2019USD ($)	Mar. 31, 2019USD ($)	Mar. 31, 2018USD ($)
Restructuring and Related Cost, Number of Positions Eliminated	40
Restructuring Charges, Total	$ 742,000	$ 742,000
Restructuring Reserve, Ending Balance		$ 24,000